When Glucocorticoids Fail in Sjögren Syndrome with Cryoglobulinemic Membranoproliferative Glomerulonephritis

Clinical Scenario

This protocol applies to patients with Sjögren syndrome who have concurrent cryoglobulinemic membranoproliferative glomerulonephritis (MPGN), positive serum cryoglobulins, and active systemic disease. Management of systemic disease is guided by organ-specific severity according to ESSDAI definitions, with particular attention to manifestations of cryoglobulinemic-associated vasculitis.

First-Line Target Not Reached

Escalation Trigger

Initial glucocorticoid therapy — appropriate for the severity of renal cryoglobulinemic MPGN — did not achieve the required reduction of ≥3 points in the global ESSDAI score. This protocol defines the structured next step following that failure.

Next-Line Approach (partial summary)

This protocol incorporates rituximab as the primary agent, with consideration of additional interventional options — the complete regimen, sequencing, and criteria remain in the full protocol.

Clinical target: Reduction of ≥3 points in the global ESSDAI score.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-216114

Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions.

The best indication is probably for symptoms linked to cryoglobulinemic-associated vasculitis.

The use of rituximab may be considered in patients with severe, refractory systemic disease, and that the best indication is probably for symptoms linked to cryoglobulinemic-associated vasculitis.

With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of >=3 points in the global ESSDAI score.

View source ↗